Versatope Therapeutics

Tomorrow, our CEO Dr. Christopher Locher will present at the Precision EV Forum 2024! 🎤   He’ll deliver an insightful talk titled "Vaccine and Therapeutic Delivery by Engineering Recombinant Extracellular Transport Vesicles."   Dr. Locher will discuss: ➡️ Cell-specific targeting using surface antibodies and affibodies for precision delivery ➡️ How genetic engineering enhances safety and versatility ➡️ Scaling up production with bioreactors and advanced analytical methods   This event is a fantastic opportunity for us to further explore the future of extracellular vesicles in precision medicine! Stay tuned for updates, and don't miss out on the cutting-edge work happening at Versatope.   Learn more about the Precision EV Forum here: https://lnkd.in/eKazgYZU

Great to meet Dr Christopher Locher, CEO of Versatope Therapeutics, today with my colleagues A/Prof Danielle Stanisic and Prof Michael Good and hear about the interesting work of this company on nano-sized vesicles to display vaccine targets. We need new and improved vaccines to give people choices so work like this (funded by the US National Institutes of Health) is so important. Likewise, the exchange of knowledge that face-to-face discussions enable is invaluable. #research #innovation Griffith University Institute for Biomedicine and Glycomics

Our CEO, Dr. Christopher Locher, will present NEXT WEEK at OPTIONS XII for Control of Influenza in Brisbane, Australia, where he'll highlight our innovative flu vaccine candidate, VT-105! 💉✨ In his talk, "A Matrix 2 Protein Vaccine from Bacterial Vesicles Protects Against Diverse Strains of Influenza," Dr. Locher will share exciting preclinical results on VT-105’s ability to protect against H1N1 and H5N1. 🔬 Key Takeaways: 💡 VT-105 reduced viral loads and protected against disease in preclinical studies. 💡 Strong immune response with high antibody levels. 💡 Effective protection against H5N1 in preclinical studies. This breakthrough vaccine uses bacterial vesicles to deliver M2 protein, overcoming past challenges. As we move toward clinical development, VT-105 shows great potential to address the global flu threat. Stay tuned for more updates as we work to advance this cutting-edge vaccine candidate! #Influenza #H5N1 #Vaccines #Biotech #Innovation #PublicHealth #FluVaccine

Our CEO Christopher Locher spent last week in Portugal, at the 18th Vaccine Congress in Lisbon. During Session 2, Florian Krammer presented new findings on H5N1 avian influenza, shedding light on its spread from wild birds to various mammals, including mass die-offs in South American seals, and now even dairy cattle in the U.S. This marks a troubling development, with H5N1 adapting to new environments. While there's no human-to-human transmission yet, the risk of reassortment with seasonal influenza looms.   Versatope Therapeutics presence at this event is important, positioning the company at the forefront of innovative vaccine development. Our efforts in developing a pan-influenza vaccine (VT-105) could prove crucial in addressing the unpredictable future of influenza strains like H5N1. Learn more about our technology: https://lnkd.in/gnABWU5 #VaccineDevelopment #LifeSciences #therapeutics #InfluenzaVaccine

Exciting Announcement from Versatope Therapeutics! 🦠💉   We have officially launched a clinical development team to advance VT-105, our groundbreaking universal influenza A vaccine candidate! This marks a significant milestone in the journey toward a universal flu vaccine, targeting a broad range of diverse, seasonal and pandemic influenza strains.    Please join us in welcoming: 🔸 Mammen (Anza) Mammen, Jr., M.D., FACP, FIDSA 🔸 Robert B. Belshe 🔸 Candice Del Rio, MS, BSN, RN 🔸 Tim Myott, CQA   The newly established team is focused on moving VT-105 through clinical trials, bringing us closer to a future where we can better protect vulnerable populations from seasonal flu epidemics and potential pandemics.   Stay tuned for more updates as we continues to break new ground in the fight against infectious diseases. https://lnkd.in/e7_uKSTD   Prnewswire #Vaccines #Influenza #Biotech #HealthcareInnovation #VersatopeTherapeutics #ClinicalDevelopment #UniversalFluVaccine

What works well to create a company culture? To celebrate our student interns' accomplishments in the great outdoors. https://lnkd.in/eF5dUPNi

We are happy to see student interns learn the basics of biotechnology in an industry setting.

Versatope Therapeutics has received an #SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) for up to $3 million over the next three years! We are thrilled to share that Versatope has been awarded grants to advance the development of a groundbreaking #malaria vaccine. This support not only signifies a significant milestone for Versatope but also represents a crucial step forward in #GlobalHealth. We have also been awarded a Stage 1 grant from the MassVentures START program, which places Versatope in the top 2.25% of companies in #Massachusetts receiving both grants. Malaria remains one of the deadliest diseases worldwide, and innovative solutions like this vaccine are essential in our quest to eradicate it. Kudos to the Versatope team for their dedication and pioneering work in this field. Let's continue to support and celebrate such impactful advancements in science and #healthcare! 💉🌍 https://lnkd.in/esnvt9UZ #HealthcareInnovation #VaccineDevelopment PR Newswire

Versatope Therapeutics is honored to join the MassVentures community and the many successful companies that have progressed through its START program. https://lnkd.in/eU7RTEDB

The Convergence Forum in Cape Cod #cvforum24 brought together a top notch line up of speakers. A huge thanks to our representatives in Washington, D.C. such as Jake Auchincloss for staying engaged with our community.